PREAMBLE
The American College of Cardiology (ACC) and the American Heart Association (AHA) recognize the importance of refining the lexicon used to describe the process and outcomes of clinical care, whether in randomized trials, observational studies, registries, or quality improvement initiatives. Broad professional agreement on a common vocabulary with common definitions will facilitate cross-study comparisons or, when advantageous, combining of data across studies and improving the assessment of any project's generalizability to clinical practice. To further efforts aimed at standardizing such a lexicon, the ACC and AHA have undertaken to develop and publish clinical data standards-sets of standardized data elements and corresponding definitions that can be used in a variety of data collection efforts for a range of cardiovascular conditions. It is hoped that these clinical data standards will do the following: 1. improve cross-comparison of results and clinical outcomes between different trials and registries; 2. facilitate the development and conduct of future registries, at both hospital and national levels, by providing a list of major variables, outcomes, and definitions; 3. facilitate measurement for quality improvement programs; and 4. become the basis for a standardized medical documentation process with the anticipation that the medical record will progress to an electronic format.
The ACC/AHA Task Force on Clinical Data Standards makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group were required to complete and submit a disclosure form showing all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the ACC/ AHA Task Force on Clinical Data Standards, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. Writing Committee members' relationships with industry are listed in Appendix C. Relationships with industry for official peer reviewers are listed in Appendix D.
The ACC/AHA Task Force on Clinical Data Standards selects cardiovascular conditions and procedures that would benefit from the creation of a data standard set. Experts in the subject are selected to examine/consider existing data standards and develop a comprehensive, yet not exhaustive, data standard set. Users should understand that when undertaking a data collection effort, only a subset of the elements contained in a clinical data standards listing may be needed or, conversely, they may want to consider whether it may be necessary to collect some elements not listed. For example, in the setting of a randomized clinical trial of a new drug, additional information would likely be required regarding study procedures and drug therapies.
The ACC and AHA aim to standardize the language used to describe cardiovascular diseases and procedures, enhance consistency in cardiology, and increase opportunities for sharing data across various data sources. The ultimate goal of ACC/ AHA clinical data standards is to contribute to the infrastructure necessary for accomplishing the ACC/AHA's mission of fostering optimal cardiovascular care and disease prevention.
The ACC and AHA support their members' goal to improve cardiovascular care and disease prevention through professional education, promotion of research, development of guidelines and standards for cardiovascular care, and fostering policy that supports optimal patient outcomes. The ACC and AHA recognize the importance of the use of clinical data for patient management, in the assessment of patient outcomes, and in research efforts focused on improving clinical treatment of patients.
As a component of this objective, the ACC/AHA clinical data standards concentrate on the identification, definition, and standardization of data corresponding with various clinical topics in cardiology. The primary goal of clinical data standards is to assist in the collection of data by providing an initial platform of data elements and corresponding definitions applicable to various disease conditions in cardiology.
These key elements and definitions are a compilation of variables applicable in the measurement of patient clinical management and outcomes, and for research and epidemiological assessments.
The Health Insurance Portability and Accountability Act (HIPAA) privacy regulations, which went into effect in April 2003, have heightened all practitioners' awareness of our professional commitment to safeguard our patients' privacy. Our goal is to treat every patient's health information with the same respect and courtesy as their person. The HIPAA privacy regulations (http://www.hhs.gov/ocr/ combinedregtext.pdf, page 31) specify which information elements are considered "protected health information." These elements may not be disclosed to third parties (including registries and research studies) without the patient's written permission. Protected health information may be included in databases used for health care operations under a data use agreement. Research studies using protected health information must be reviewed by an institutional review board or a privacy board.
We have included identifying information in all clinical data standards to facilitate uniform collection of these elements when appropriate. For example, a longitudinal clinic database may contain these elements, since access is restricted to the patient's caregivers. On the other hand, registries may not contain protected health information unless specific permission is granted by each patient. These fields are indicated as protected health information in the data standards.
Our understanding of the importance of data element standardization, the backbone of clinical care, clinical research, and quality performance measurement derives from experience with clinical care, clinical research, and quality performance measurement. In clinical care, caregivers communicate with each other through a common vocabulary. The integrity of clinical research depends in large part on firm adherence to pre-specified procedures for patient enrollment and follow-up; these procedures are guaranteed through careful attention to definitions enumerated in the study design and case-report forms. When data elements and definitions are standardized across studies, comparison, pooled analysis, and meta-analysis are enabled, thus deepening our understanding of individual clinical trials.
The recent development of quality performance measurement initiatives, particularly those for which comparison of providers is an implicit or explicit aim, has further raised awareness among the professional community about the importance of data standards. For the first time, a wide audience, including non-medical professionals such as payers, regulators, and consumers, may draw conclusions about care and outcomes. For understanding and comparison of care patterns and outcomes to be fair, the data elements that compose the descriptions of these patterns and outcomes of care must be clearly defined, consistently used, and properly interpreted by a broader audience than ever before.
Paul A. Heidenreich, MD, MS, FACC, Chair, ACC/AHA Task Force on Clinical Data Standards
I. INTRODUCTION
The current era of clinical cardiac electrophysiology (EP) began in the late 1960s with the introduction and growth of EP laboratories. What began as a diagnostic field focused on improving our understanding of cardiac conduction defects, then spread into diagnostic studies of patients with tachyarrhythmias, both supraventricular and ventricular. This discipline has now evolved into one in which therapeutic ventures have displaced diagnosis as the major focus. Therapies directed by electrophysiologists encompass two major types: 1) catheter-based, for cure or palliation of tachyarrhythmias; and 2) device-based, for both bradyarrhythmias as well as tachyarrhythmias. More recently, EP has influ-enced the treatment of patients with heart failure, using unique pacing modalities. This discipline will continue to evolve, and one can foresee EP catheters and devices being utilized to deliver novel molecular and genetic therapies in the future.
Increasing emphasis is being placed on the outcomes of treatment. If we are to evaluate the results of new, as well as established, treatments, it is necessary to characterize patients accurately. This, in turn, requires the creation of databases that not only record patient attributes, but permit comparison between patient groups. Description of patient characteristics, as well as treatment outcomes, is vital not only to researchers, but to practitioners. Every physician involved in patient care is obligated to critically evaluate the results of the care they deliver. If we do not question the results of our interactions with patients, we will perpetuate misconceptions, repeat previous mistakes, and retard the advancement of medical science. It is in this spirit that we present this first edition of the ACC/AHA/HRS Electrophysiology Clinical Data Standards.
It is recognized that cardiac arrhythmias and electrophysiologic properties are influenced to a large extent by a patient's age. Normal values of electrophysiologic and electrocardiographic parameters for persons under 18 years of age differ from those of adults. The electrophysiologic parameters for persons under age 18 vary and change with growth. The normal values provided in this document apply to persons over age 18. Although certain arrhythmias may occur primarily or exclusively in the pediatric or adult populations, the committee feels there is merit in providing one document, for purposes of continuity and inclusiveness. In constructing this document we have tried to use terms general enough to make the document useful and appropriate for both pediatric and adult electrophysiologists.
This document is meant to serve two major purposes. The first goal is to serve as the basis for databases employed in clinical research as well as practice. Our intent was to be as inclusive as possible. We have tried to provide a comprehensive instrument that would prove useful to physicians and other professionals involved in the care of patients with cardiac arrhythmias or implanted rhythm management devices. The intent of this document is not to mandate data to be collected nor do we expect that all the data elements will be utilized in every setting. Rather, we expect practitioners will pick and choose data elements as appropriate for individual projects.
The second major goal of this project is to provide standard definitions of terms relevant to the care of patients with arrhythmias and implanted rhythm management devices. We anticipate this will facilitate communication and promote a common language to foster meaningful comparisons and assessment of analyses and outcomes. Some definitions are arbitrary because of a lack of sufficient data to provide a rational pathophysiologic basis. In such cases, we have tried to incorporate common usage, with the expecta-tion that future work will result in data to eliminate such shortcomings.
The writing committee anticipates that the EP data standards will prove useful in several settings:
• Clinical programs, where many providers and health plans work together to achieve specific goals for the care of patients with arrhythmias and arrhythmia management devices. Data standards will assist in the organization and design of electronic medical information initiatives, such as electronic medical records, pharmacy and other clinical databases, or computerized decision support. • Clinical research, including prospective registries and randomized controlled trials (RCTs). Meta-analyses of RCTs would be particularly strengthened by the use of standardized data for key variables. • Quality-performance measurement initiatives. Data standards will especially facilitate interpretation for nonmedical users, such as payors, regulators, and consumers.
II. METHODOLOGY

A. Writing Committee Composition
The ACC/AHA Task Force on Clinical Data Standards selected members for the ACC/AHA/HRS Writing Committee to Develop Clinical Data Standards for Electrophysiology. The committee consisted of 14 members who are active in clinical research in adult EP, as well as heart failure and general cardiology. The committee included membership from across the U.S., so as to ensure balance in the selection of data elements and consideration of variations in practice. To ensure consistency between the clinical data standards and other ACC/AHA/HRS standards, the Task Force appointed representatives who had served on other ACC/AHA Guideline Writing Committees.
B. Review of Literature and Existing Data Definitions
The The EP data standards are meant to provide data elements that parallel and complement other ACC and AHA standards, specifically the guidelines and the performance measures. These data were developed simultaneously with other data standards. Research articles, clinical trials, and reference sources were consulted as needed and are cited throughout this document.
C. Defining Data Elements
Members of the Writing Committee drafted definitions. Writers were encouraged to write definitions broad enough to be applicable in a variety of data collection settings, but specific enough that the data elements can be uniformly interpreted. In addition, the committee compiled a dictionary of common definitions for arrhythmias mentioned throughout this document (see Appendix A) to further supplement and support consistency in data collection of the elements and definitions contained in the main document. Data definitions were linked whenever possible to the evidence-based national guidelines. To ensure consistency across ACC/AHA clinical data standards, writers used an existing ACC/AHA definition verbatim unless there was a reason related to EP to change that definition.
D. Relation to Other Data Standards
This committee has reviewed the ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial Fibrillation (5) . That document addresses certain aspects of data collection in patients with atrial fibrillation in more detail than is covered in this document. The committee anticipates that for certain purposes, use of that document is more appropriate.
In an effort to maintain consistency of definitions across the data standards documents, the committee also reviewed the ACC Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes (3) and the ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Adults With Chronic Heart Failure (4).
E. Consensus Development
The ACC/AHA data standards are consensus, teamwritten documents that are based on judgments of experts in the field of cardiology. This Writing Committee met several times, both in person and through conference calls, over the course of several months to define and refine the data elements. Throughout the creation of the data element set, consensus was developed through discussions (either during face-to-face meetings or conference calls), e-mails, and sometimes written votes.
F. Peer Review, Public Comment, and Board Approval
The set of EP data elements was independently reviewed by official reviewers nominated by the ACC, the AHA, and the Heart Rhythm Society (HRS), as well as the ACC/AHA Task Force on Clinical Data Standards and independent content reviewers. To increase its applicability further, this document was posted on the ACC Web site (www.acc.org) for a 30-day public comment period from March 23 through April 21, 2005. This document was approved for publication by the governing bodies of the ACC, the AHA, and the HRS.
The Writing Committee anticipates these data standards will require regular review and updating, just as is the case with guidelines and performance measures. At the anniversary of the data standards publication, the Writing Committee chair, in conjunction with the Writing Committee members, will review the data standards to ascertain whether or not modifications should be considered. To keep current, whenever a relevant guideline is updated the associated data standards will be reviewed and updated to reflect those changes.
III. ELECTROPHYSIOLOGY CLINICAL DATA STANDARDS ELEMENTS AND DEFINITIONS
A. Patient Demographics
Patient demographic information is used for patient identification for longitudinal care, for demographic grouping to assess issues of access and care quality for traditionally disadvantaged groups, and for risk adjustment. Association of any health information with unique patient identifiers and/or demographic information that can be linked to the individual patient (indicated by an asterisk) identifies the dataset as "protected health information." Unique patient identification information (Social Security number or medical record number) is necessary and appropriate for longitudinal clinical care, but given current legislation protecting patients' privacy (7) , is not included in multi-institution registries unless appropriate informed consent is obtained from all patients. For other uses, patient privacy concerns may need to be considered by hospital privacy officers and/or institutional review board. members on a pre-paid basis. • None: Refers to individuals with no or limited health insurance; thus, the individual is the payor regardless of ability to pay. Only mark "None" when "self" or "none" is denoted as the first insurance in the medical record.
DATA ELEMENT DEFINITION
Government payor type
If the patient's primary insurance payor for this encounter is "Government," choose the type of government insurance: 
B. Patient History
Information about patients' medical history is important in quality performance measurement, clinical research, and clinical care. The frequency, severity, and duration of symptoms associated with arrhythmias are of prime importance in determining appropriate therapy. History of non-cardiac conditions may denote absolute or relative contraindications to various therapies and may significantly impact outcome and prognosis. Inclusion of data elements pertinent to patient history is therefore important to clinical decision-making, to design of quality performance measures, and to risk-adjusted outcomes assessment. For most purposes, these data elements can be recorded as either present or absent. Year of onset may be helpful, especially when data collection is used for longitudinal clinical follow-up. More detailed information about severity of each condition (e.g., record of prior hospitalizations or specifics of therapy for the condition) might be considered for certain users.
In addition to general non-cardiac and cardiac history we have included space to record detailed history of arrhythmias. Previously documented arrhythmias may be important for determination of appropriate therapy, as well as carrying prognostic information. Knowledge of medications being taken at the time of spontaneous arrhythmia occurrence is important for several reasons:
• Medications may facilitate occurrence of arrhythmias, in association with QT prolongation, as well as re-entrant arrhythmias not related to QT prolongation. • Medications may alter the clinical manifestations of arrhythmias, for example by slowing tachycardias, or by worsening atrioventricular or intraventricular conduction.
Other factors may be important to document, such as the standard electrocardiogram (ECG), both in sinus rhythm, as well as during tachycardias. The standard ECG may provide critical prognostic as well as diagnostic information. Abrupt loss of postural tone (collapse) without reported loss of consciousness.
DATA ELEMENT DEFINITION
Presentations Associated With Arrhythmia
• Provide date of first documented episode of "drop attack." • Specify number of episodes. If multiple episodes have occurred, provide frequency. Angina due to arrhythmia History of angina before the current admission. "Angina" refers to evidence or knowledge of symptoms before this acute event described as chest pain or pressure, jaw pain, arm pain, or other equivalent discomfort suggestive of cardiac ischemia. Date of most recent episode may be helpful.
Dyspnea
Patient experiences frequent uncomfortable awareness of breathing in one or both of the following circumstances (specify): • Resting in a sitting position • Exerting him/herself Year of onset may be helpful.
Fatigue
Patient describes history of unusual tiredness and inability to perform usual activities.
Year of onset may be helpful.
HF caused by arrhythmia
There are two common situations in which arrhythmias cause HF symptoms:
1. An acute arrhythmia may precipitate acute HF, most often with acute pulmonary edema. 2. A persistent arrhythmia may precipitate symptoms of chronic HF, with a more varied presentation. Cardiac arrest due to arrhythmia "[Sudden] cardiac arrest is the sudden cessation of cardiac activity so that the victim becomes unresponsive, with no normal breathing and no signs of circulation. If corrective measures are not taken rapidly, this condition progresses to sudden death. Cardiac arrest should be used to signify an event as described above, that is reversed, usually by CPR and/or defibrillation or cardioversion, or cardiac pacing. Sudden cardiac death should not be used to describe events that are not fatal." Specify whether cardiac arrest occurred out-of-hospital or in-hospital.
Arrhythmia History (see Appendix A for a supplemental dictionary of arrhythmia terms used throughout this section) Duration and frequency of arrhythmia
For each arrhythmia, provide the following information: Indicate the patient's medical history with respect to SVT.
• Normal (no history of SVT) • SVT -Recurrent: more than one episode of tachycardia -Persistent: episodes of tachycardia that require medical intervention (pharmacologic therapy, pacing, ablation, or cardioversion) for termination -Paroxysmal: episodes of tachycardia that terminate spontaneously -Incessant: episodes of tachycardia that resume immediately after termination • Atrial premature complexes (APC) • Atrial tachycardia (AT) -Focal ATs -Multifocal ATs • Atrial fibrillation (AF) -Initial episode of AF -Paroxysmal AF -Persistent AF -Permanent AF • Macro re-entrant AT -Cavotricuspid isthmus (CTI)-dependent AF (also typical or type I AF) -Non-CTI-dependent AF • Macro-re-entrant AT related to previous cardiac surgery 
History of Medication at Time of Arrhythmia
Antiarrhythmic agents Indicate if patient taking antiarrhythmic agent(s) (including digitalis, beta-adrenergic blocking agents, or calcium channel blockers) at time of arrhythmia. Specify drug(s).
Non-antiarrhythmic cardiovascular agents
Indicate if patient taking non-antiarrhythmic cardiovascular agent(s) at time of arrhythmia. Specify drug(s).
Non-cardiovascular drugs
Indicate if patient taking non-cardiovascular drug(s) at time of arrhythmia. Specify drug(s).
Specific ECG Patterns
Simultaneous ECG leads Multiple ECG lead recordings performed at the same time; indicate number of simultaneous ECG leads recorded. P-wave duration Time required for complete depolarization of both right and left atria. Duration of P-wave in milliseconds, measured from at least 3 simultaneous ECG leads, preferably including leads I, II, and V 1 .
PR interval
Longest measured time from onset of P wave to onset of QRS complex in any given ECG lead.
QRS duration
Time required for complete depolarization of the right and left ventricles, measured in milliseconds from simultaneous (preferably 3 or more) ECG leads, including I, II, and V 1 , from the onset to the termination of the QRS.
Epsilon wave
Delayed ventricular depolarization wave, usually seen in the early precordial leads (V 1 thorough V 3 ) as a notch or fragmented potential at the end of the QRS or early during the ST-segment. It signifies delayed (slowed or fractionated) ventricular depolarization (in the right ventricle and seen with right ventricular cardiomyopathy [arrhythmogenic right ventricular dysplasia or cardiomyopathy]). It correlates with the late potentials seen on the signal-averaged ECG, and it has also been called a "ventricular post-excitation wave." (8): 
D. Laboratory Data
Many routine and specialized laboratory tests may be relevant to management and tracking of patients with cardiac arrhythmias. Ejection fraction may influence the hemodynamic consequences of arrhythmias, both supraventricular and ventricular, and has a significance influence on prognosis. Ejection fraction may relate to risk of toxicity associated with pharmacologic antiarrhythmic therapy. Thus, accurate quantification of ejection fraction, as well as the presence of other manifestations of ventricular dysfunction, such as ventricular aneurysms, may be important to document in patients with arrhythmias. Evaluation of myocardial ischemia and coronary anatomy is usually not necessary in patients with supraventricular arrhythmias and conduction abnormalities, unless indicated by clinical presentation. However, with the exception of patients who have one of the well-recognized syndromes associated with idiopathic ventricular tachycardia, most patients with ventricular arrhythmias should have evaluation for ischemia. Ischemia may directly cause certain ventricular tachyarrhythmias. Furthermore, correction of ischemia may lessen the frequency and severity of ventricular arrhythmias and improve the overall prognosis. 
DATA ELEMENT DEFINITION
QT dispersion
Difference between the longest and shortest individually measured QT c interval in each of the 12 leads of the standard ECG (or, in some cases, in precordial mapping). -A positive test for neurocardiogenic syncope characterized by either: 1) a drop in systolic blood pressure Ͻ80 mm Hg with a slowing or no changes in heart rate accompanied by typical symptoms (vasodepressor response), or 2) a slowing in sinus rate or sinus arrest (asystole, cardioinhibitory response). -A positive test for POTS is characterized by an orthostatic rise in heart rate of Ͼ30 bpm above baseline or Ͼ120 bpm within the first 10 min of head-up tilt without significant fall in systolic blood pressure (Ͻ10 mm Hg), accompanied by typical symptoms. -A negative test is defined as completion of the testing protocol without significant hypotension or typical symptoms. -An equivocal test is defined as failure to induce syncope or meet the aforementioned criteria. • Response to carotid sinus massage.
Exercise Testing
G. Electrophysiology Study
Not all elements of the electrophysiologic evaluation may be necessary or appropriate for every patient. 
DATA ELEMENT DEFINITION
Indications for Diagnostics
Drugs administered for therapy/ diagnostics
Indicate therapeutic and/or diagnostic drugs administered, such as isoproterenol, epinephrine, dopamine, aminophylline, atropine, adenosine, beta-blockers, ibutilide, verapamil, procainamide, and so on. 
Diagnostic Evaluation (see Appendix A for a supplemental dictionary of arrhythmia terms used throughout this section) a. Sinus Node Function
I. Patient Management as a Result of Electrophysiology Studies
DATA ELEMENT DEFINITION
Observation and reassurance No specific antiarrhythmic therapy warranted.
Pharmacologic therapy recommended
Indicate the pharmacologic therapy recommended as a result of the EP study: • Antiarrhythmic drugs. Indicate specific drugs (i.e., digitalis, beta-blocker, calcium channel blocker, primary antiarrhythmic agents). • Nonantiarrhythmic drugs (i.e., aspirin, oral anticoagulation, etc.)
Term Definition
Atrial premature complexes A depolarization of the atrium which occurs with a coupling interval shorter than that resulting from the intrinsic heart rhythm. Atrial tachycardia A usually regular cardiac arrhythmia arising from the atrium with a rate Ͼ100 bpm (cycle length Ͻ600 ms).
• Focal atrial tachycardias are characterized by usually regular atrial activation from atrial areas with centrifugal spread, with rates usually between 100 to 250 bpm (rarely at 300 bpm). They may arise from right or left atrial sites. • Multifocal atrial tachycardia-an irregular tachycardia characterized by 3 or more different P-wave morphologies at different rates, most commonly associated with underlying pulmonary disease.
Atrial fibrillation (AF)
A cardiac arrhythmia arising from the atrium with an atrial rate Ͼ300 bpm and an irregularly irregular ventricular response in the presence of conduction. AF can be further characterized as: • First detected AF • Paroxysmal AF: AF is self-terminating within 7 days of recognized onset. • Persistent AF: AF is not self-terminating within 7 days, or is terminated electrically or pharmacologically. • Permanent AF: cardioversion failed or not attempted. Macro-re-entrant atrial tachycardia A cardiac arrhythmia arising in the atrium which has a regular rate typically between 250 and 350 bpm (cycle length 240-170 ms) in the absence of antiarrhythmic drugs. • Cavotricuspid isthmus (CTI)-dependent atrial flutter (also typical or type I atrial flutter): a reentrant tachycardia following a counterclockwise (typical) or clockwise (reverse typical) rotation pattern around the tricuspid annulus resulting in a sawtooth pattern of atrial activation on inferior ECG leads. This is amenable to curative catheter ablation of the CTI. • Non-CTI dependent atrial flutter: macro-re-entrant tachycardias dependent upon an atrial scar that creates conduction block and a central obstacle for re-entry. Prior cardiac surgery involving the atrium is a common cause.
Sinus tachycardia (ST)
A cardiac arrhythmia emanating from the sinus node at a rate Ͻ100 bpm (cycle length: Ͻ600 ms) which demonstrates a gradual onset and termination and is in keeping with the level of physical, emotional, pathological, or pharmacological stress.
Inappropriate sinus tachycardia
Increase in sinus rate unrelated to, or out of proportion with, the level of physical, emotional, pathological, or pharmacological stress. Can be persistent or intermittent/paroxysmal. Postural orthostatic tachycardia syndrome Orthostatic rise in heart rate of Ͼ30 bpm above baseline or Ͼ120 bpm within the first 10 min of head-up tilt, accompanied by palpitations, and no significant (Ͻ10 mm Hg) fall in systolic blood pressure. AV node re-entry A regular SVT which results from re-entry within the AV node and/or perinodal atrial tissue. Subclasses are: • Slow-fast • Fast-slow • Slow-slow Junctional tachycardia A supraventricular arrhythmia that arises from the atrioventricular junction, has a rate Ͼ60 bpm (cycle length: Ͻ1,000 ms), and may demonstrate dissociation from atrium or ventricle. Within this category are discrete subsets with distinctly different natural histories: • Congenital junctional ectopic tachycardia: observed exclusively in the pediatric population, characterized by high heart rates and refractoriness to drug therapy. This condition may be associated with high mortality if not diagnosed or if recognized late and not treated appropriately. • Postoperative junctional tachycardia: similar to congenital junctional ectopic tachycardia, but observed in pediatric patients after cardiac surgery. • Focal junctional tachycardia: a rare, highly symptomatic tachycardia found in young adults, often exercise-related, with rates of 110 to 250 bpm. May cause tachycardia-related myopathy. • Non-paroxysmal junctional tachycardia: a benign tachycardia with rates of 60 to 120 bpm and a typical "warm-up" and "cool-down" pattern. It may indicate underlying conditions such as digitalis toxicity. • Other AV re-entrant tachycardia (AVRT)
A re-entrant arrhythmia whose circuit involves the atrium, the AV node, the ventricles, and one or more accessory AV connections. AVRT can be further classified as orthodromic AVRT, in which conduction through the AP occurs from the ventricle to the atrium, or antedromic AVRT, in which conduction through the AP occurs from the atrium to the ventricle.
Wolff-Parkinson-White syndrome
Patients with tachycardia in association with ventricular pre-excitation. 
Continued on next page
Ventricular Tachycardias
Ventricular tachycardia (VT) VT is a cardiac arrhythmia of 3 or more consecutive complexes in duration emanating from the ventricles at a rate Ͼ100 bpm (cycle length: Ͻ600 ms). Types of VT: • Spontaneous: spontaneous occurrence of VT as assessed through electrocardiographic recording. • Induced: VT induced through programmed ventricular stimulation, or delivery of external energy, such as radiofrequency current. • Sustained: VT Ͼ30 s in duration or requiring termination due to hemodynamic compromise in Ͻ30 s.
• Nonsustained/unsustained: 3 or more beats in duration, terminating spontaneously in Ͻ30 s. • Bidirectional: VT with a beat-to-beat alternans in the QRS frontal plane axis, often associated with digitalis toxicity. • Exercise-induced: VT initiated through exercise. • Narrow complex: A VT with a QRS duration is shorter than 120 ms. VT, monomorphic
• Sustained: VT with a stable single QRS morphology.
• Nonsustained/unsustained: nonsustained VT with a single QRS morphology.
• Repetitive: Paroxysmal and frequent (often incessant) nonsustained VT, usually in the absence of structural heart disease, with a single morphology and normal intervening sinus beats.
VT, polymorphic
Types of polymorphic VT:
• Sustained: VT with a changing or multiform QRS morphology at cycle length Ͼ180 ms.
• Nonsustained/unsustained: nonsustained VT with a changing QRS morphology at cycle length Ͼ180 ms.
• Catecholaminergic: polymorphic VT associated with syncope and/or cardiac arrest triggered by emotion or exercise in patients whose baseline ECG is normal.
Premature ventricular complexes (PVC)
A depolarization of the ventricle which occurs with a coupling interval shorter than that resulting from the intrinsic heart rhythm. Ventricular couplet Two consecutive PVCs separated by a maximum interval Ͻ600 ms. Accelerated idioventricular rhythm Ectopic ventricular rhythm with Ն3 consecutive ventricular premature beats occurring at a rate Ͻ100 bpm (cycle length: Ͼ600 ms) but faster than the normal ventricular intrinsic escape rate of 30 to 40 bpm (cycle length: 2,000 to 1,500 ms).
VT storm
History of VT storm as manifested by one of the following:
• Incessant VT, typically present in Ͼ50% of a 24-h period.
• A series of VT episodes triggering implantable cardioverter-defibrillator discharges within a short time period (e.g., 20 discharges within 30 min). Adenosine-sensitive VT VT responsive to adenosine therapy for termination. Verapamil-sensitive VT Idiopathic VT responsive to verapamil administration and may exhibit either RBBB or LBBB morphology, though term usually applied to left ventricular septal tachycardias Ventricular flutter A regular (cycle length variability 30 ms or less) ventricular arrhythmia approximately 300 bpm (cycle length: 200 ms) with a monomorphic appearance; no isoelectric interval between successive QRS complexes.
Ventricular fibrillation
Rapid, usually more than 300 bpm (cycle length: 180 ms or less), grossly irregular ventricular rhythm with marked variability in QRS cycle length, morphology, and amplitude.
Torsades de pointes
Patient has documented history of torsades de pointes as characterized by VT associated with a long QT or QT c , and electrocardiographically characterized by twisting of the peaks of the QRS complexes around the isoelectric line during the arrhythmia: • Typical, initiated following "short-long-short" coupling intervals. • 
